Spectrum's transfer agent is Computershare and can be contacted at:
Computershare Trust Company, N.A.
P.O. Box 43070
Providence, Rhode Island 02940-3070
Inside the US 800.962.4284
Outside the US 781.575.3210
Spectrum currently has three drug candidates that are no longer under active development; SPI-339, SPI-376 and SPI-392. Spectrum still retains the intellectual property rights to these products, and intends to out-license these compounds if possible. Currently, there are no plans to resurrect these products into active development.
This Web site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the beliefs of the Company's management as well as assumptions made by and information currently available to the Company's management. Readers should not put undue reliance on these forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Spectrum Pharmaceuticals, Inc.'s actual results may differ materially from the results projected in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed in the Company's most recent Form 10-K and 10-Qs. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this filing except as required by law.